Johnson & Johnson Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront

Johnson & Johnson sign outside its world headquarters in New Brunswick, New Jersey. File photo; capture date not supplied. Photo: Johnson & Johnson.
URL has been copied successfully!

Johnson & Johnson sign outside its world headquarters in New Brunswick, New Jersey. File photo; capture date not supplied. Photo: Johnson & Johnson.

Johnson & Johnson announced Monday, November 16, that it signed a definitive agreement to buy eye-disease drug developer Ollin Biosciences for $2.2 billion upfront, with up to about $1.125 billion in additional payments tied to regulatory and commercial milestones.

The proposed acquisition would bring J&J an experimental antibody called OLN324, which is in Phase 3 development for serious retinal diseases. The deal has not closed, and the medicine is not an approved treatment.

J&J expects the acquisition to close before the end of 2026, subject to regulatory approvals and customary closing conditions, according to its announcement.

A drug candidate aimed at two disease pathways

OLN324 is being developed for conditions including wet age-related macular degeneration and diabetic macular edema. Both are retinal diseases that can cause vision loss.

The antibody is designed to act on two proteins involved in retinal disease: vascular endothelial growth factor, or VEGF, and angiopoietin-2, or Ang2. J&J says its small antibody format and strong activity against Ang2 could improve control of fluid in the retina.

The company hopes that approach could give patients better disease control and longer intervals between treatments. Those are development goals, not established benefits from an approved medicine.

A separate $750 million development agreement

J&J also plans a separate agreement with Blackstone Life Sciences to fund OLN324’s Phase 3 development. That arrangement is contingent on the Ollin acquisition closing.

Under the funding terms, Blackstone would pay J&J $750 million over several years to fully fund that Phase 3 work. In return, Blackstone would be eligible for certain regulatory and sales milestone payments, along with single-digit royalties.

The $750 million is development funding, not an extra acquisition payment to Ollin’s owners.

J&J said it would explain the transaction’s accounting treatment on or before closing.

JBizNews Desk | Health

© JBizNews.com. All rights reserved for article text. Photograph provided by Johnson & Johnson for editorial use in stories about the company and remains subject to its copyright. Unauthorized reproduction or redistribution of article text is strictly prohibited.

Share this story:
Share on Facebook
Share by Email
X (Twitter)
Follow Me
Tweet
Whatsapp
LinkedIn
Copy link